| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
DURHAM, N.C.—Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis precision immunotherapy technology platform, recently announced that it had entered into an option agreement with Pharmstandard International S.A. and Actigen Ltd. under which the company has an option to license a group of fully human anti-PD1 monoclonal antibodies (PD1 checkpoint inhibitors) and related technology.
 
Results of a preclinical study of a murine analogue of Rocapuldencel-T (Roca-T), the company’s investigational dendritic cell therapy for the treatment of metastatic renal cell carcinoma (mRCC), were recently presented at the ASCO-SITC Clinical Immuno-Oncology Symposium. The study looked at various combinations with a murine PD1 monoclonal antibody (anti-mPD1) and sunitinib in a mouse model of renal cell carcinoma. In this model, murine dendritic cell precursors were processed in a similar manner to that by which human monocytes are processed to manufacture Roca-T. Multiple combination dosing strategies were tested, all of which included treatment with sunitinib. Anti-mPD1 was tested both with administration two days following tumor inoculation (therapeutic administration) and with administration six days prior to tumor inoculation (prophylactic administration).
 
Of note, histologic evaluation in these studies revealed that murine dendritic cells with similar properties to Roca-T resulted in recruitment and migration of lymphocytes into the tumor microenvironment and an increase in CD8+CD28+CD45RA-memory T cells. An increase in this same type of memory T cell after seven doses of Roca-T, as measured in blood samples, correlated with longer survival in the company’s Phase 3 ADAPT clinical trial of Roca-T in mRCC patients. These findings suggest that the mechanism of action of the murine analogue of Roca-T in this model is similar to that of Roca-T in man.
 
“Data from this study support the rationale for combining dendritic cell therapy with a PD1 checkpoint inhibitor in the treatment of renal cell carcinoma,” noted Charles Nicolette, chief scientific officer of Argos Therapeutics. “These data also demonstrate the importance of the administration sequence for active immunotherapy with a murine analogue of Roca-T and a PD1 checkpoint inhibitor, along with sunitinib, and suggest that the cellular immune response must be initiated and established prior to administration of anti-PD1 and sunitinib in order to achieve synergy in this murine model of mRCC.”
 
Jeff Abbey, president and CEO of Argos Therapeutics, added: “We are pleased to have secured an option to license a group of fully human PD1 antibodies from Pharmstandard and Actigen. Provided sufficient funding is available, we expect to exercise this option and undertake the necessary preclinical studies in order to initiate clinical development of Roca-T in combination with a PD1 antibody.”

Related Topics

Published In

Volume 14 - Issue 4 | April 2018

April 2018

April 2018 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue